Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma

S. Yano, Takehiko Mori, Y. Kanda, Jun Kato, C. Nakaseko, S. Fujisawa, N. Tomita, R. Sakai, K. Shono, T. Saitoh, N. Aotsuka, N. Kobayashi, T. Saito, S. Takahashi, H. Kanamori, Shinichiro Okamoto

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with relapsed follicular lymphoma (FL). Prospective studies of reduced-intensity conditioning (RIC) have revealed that chemosensitivity at allo-SCT is the most reliable predictor of outcome; however, limited data are available for progressive/refractory disease. We report here a retrospective analysis of RIC allo-SCT for patients with FL. The purpose of this study was to elucidate the role of allo-SCT for patients with relapsed/refractory FL. We analyzed 46 patients - 11 (24%) transplanted in CR, 6 (13%) transplanted in PR and 29 (63%) with progressive/refractory disease. The estimated 5-year overall survival rate was 71.6% (95% confidence interval (CI), 51.5-84.5%). According to the disease status at transplantation, the 5-year survival rate was 80.7% (95% CI, 37.7-95.4%) in the patients with CR or PR and 66.1% (95% CI, 41.5-82.3%) in those with progressive/refractory disease (P=0.29). There were no differences in relapse/progression and non-relapse mortality between the patients with chemosensitive disease and progressive/refractory disease. Allo-SCT may be a valuable treatment option, even for patients with progressive/refractory FL.

Original languageEnglish
Pages (from-to)1299-1305
Number of pages7
JournalBone Marrow Transplantation
Volume50
Issue number10
DOIs
Publication statusPublished - 2015 Oct 1

Fingerprint

Follicular Lymphoma
Stem Cell Transplantation
Survival
Confidence Intervals
Survival Rate
Transplantation
Prospective Studies
Recurrence
Mortality

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma. / Yano, S.; Mori, Takehiko; Kanda, Y.; Kato, Jun; Nakaseko, C.; Fujisawa, S.; Tomita, N.; Sakai, R.; Shono, K.; Saitoh, T.; Aotsuka, N.; Kobayashi, N.; Saito, T.; Takahashi, S.; Kanamori, H.; Okamoto, Shinichiro.

In: Bone Marrow Transplantation, Vol. 50, No. 10, 01.10.2015, p. 1299-1305.

Research output: Contribution to journalArticle

Yano, S, Mori, T, Kanda, Y, Kato, J, Nakaseko, C, Fujisawa, S, Tomita, N, Sakai, R, Shono, K, Saitoh, T, Aotsuka, N, Kobayashi, N, Saito, T, Takahashi, S, Kanamori, H & Okamoto, S 2015, 'Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma', Bone Marrow Transplantation, vol. 50, no. 10, pp. 1299-1305. https://doi.org/10.1038/bmt.2015.158
Yano, S. ; Mori, Takehiko ; Kanda, Y. ; Kato, Jun ; Nakaseko, C. ; Fujisawa, S. ; Tomita, N. ; Sakai, R. ; Shono, K. ; Saitoh, T. ; Aotsuka, N. ; Kobayashi, N. ; Saito, T. ; Takahashi, S. ; Kanamori, H. ; Okamoto, Shinichiro. / Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma. In: Bone Marrow Transplantation. 2015 ; Vol. 50, No. 10. pp. 1299-1305.
@article{de12658cec33476d8355083906439fc7,
title = "Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma",
abstract = "Allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with relapsed follicular lymphoma (FL). Prospective studies of reduced-intensity conditioning (RIC) have revealed that chemosensitivity at allo-SCT is the most reliable predictor of outcome; however, limited data are available for progressive/refractory disease. We report here a retrospective analysis of RIC allo-SCT for patients with FL. The purpose of this study was to elucidate the role of allo-SCT for patients with relapsed/refractory FL. We analyzed 46 patients - 11 (24{\%}) transplanted in CR, 6 (13{\%}) transplanted in PR and 29 (63{\%}) with progressive/refractory disease. The estimated 5-year overall survival rate was 71.6{\%} (95{\%} confidence interval (CI), 51.5-84.5{\%}). According to the disease status at transplantation, the 5-year survival rate was 80.7{\%} (95{\%} CI, 37.7-95.4{\%}) in the patients with CR or PR and 66.1{\%} (95{\%} CI, 41.5-82.3{\%}) in those with progressive/refractory disease (P=0.29). There were no differences in relapse/progression and non-relapse mortality between the patients with chemosensitive disease and progressive/refractory disease. Allo-SCT may be a valuable treatment option, even for patients with progressive/refractory FL.",
author = "S. Yano and Takehiko Mori and Y. Kanda and Jun Kato and C. Nakaseko and S. Fujisawa and N. Tomita and R. Sakai and K. Shono and T. Saitoh and N. Aotsuka and N. Kobayashi and T. Saito and S. Takahashi and H. Kanamori and Shinichiro Okamoto",
year = "2015",
month = "10",
day = "1",
doi = "10.1038/bmt.2015.158",
language = "English",
volume = "50",
pages = "1299--1305",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma

AU - Yano, S.

AU - Mori, Takehiko

AU - Kanda, Y.

AU - Kato, Jun

AU - Nakaseko, C.

AU - Fujisawa, S.

AU - Tomita, N.

AU - Sakai, R.

AU - Shono, K.

AU - Saitoh, T.

AU - Aotsuka, N.

AU - Kobayashi, N.

AU - Saito, T.

AU - Takahashi, S.

AU - Kanamori, H.

AU - Okamoto, Shinichiro

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with relapsed follicular lymphoma (FL). Prospective studies of reduced-intensity conditioning (RIC) have revealed that chemosensitivity at allo-SCT is the most reliable predictor of outcome; however, limited data are available for progressive/refractory disease. We report here a retrospective analysis of RIC allo-SCT for patients with FL. The purpose of this study was to elucidate the role of allo-SCT for patients with relapsed/refractory FL. We analyzed 46 patients - 11 (24%) transplanted in CR, 6 (13%) transplanted in PR and 29 (63%) with progressive/refractory disease. The estimated 5-year overall survival rate was 71.6% (95% confidence interval (CI), 51.5-84.5%). According to the disease status at transplantation, the 5-year survival rate was 80.7% (95% CI, 37.7-95.4%) in the patients with CR or PR and 66.1% (95% CI, 41.5-82.3%) in those with progressive/refractory disease (P=0.29). There were no differences in relapse/progression and non-relapse mortality between the patients with chemosensitive disease and progressive/refractory disease. Allo-SCT may be a valuable treatment option, even for patients with progressive/refractory FL.

AB - Allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with relapsed follicular lymphoma (FL). Prospective studies of reduced-intensity conditioning (RIC) have revealed that chemosensitivity at allo-SCT is the most reliable predictor of outcome; however, limited data are available for progressive/refractory disease. We report here a retrospective analysis of RIC allo-SCT for patients with FL. The purpose of this study was to elucidate the role of allo-SCT for patients with relapsed/refractory FL. We analyzed 46 patients - 11 (24%) transplanted in CR, 6 (13%) transplanted in PR and 29 (63%) with progressive/refractory disease. The estimated 5-year overall survival rate was 71.6% (95% confidence interval (CI), 51.5-84.5%). According to the disease status at transplantation, the 5-year survival rate was 80.7% (95% CI, 37.7-95.4%) in the patients with CR or PR and 66.1% (95% CI, 41.5-82.3%) in those with progressive/refractory disease (P=0.29). There were no differences in relapse/progression and non-relapse mortality between the patients with chemosensitive disease and progressive/refractory disease. Allo-SCT may be a valuable treatment option, even for patients with progressive/refractory FL.

UR - http://www.scopus.com/inward/record.url?scp=84943422621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943422621&partnerID=8YFLogxK

U2 - 10.1038/bmt.2015.158

DO - 10.1038/bmt.2015.158

M3 - Article

C2 - 26168068

AN - SCOPUS:84943422621

VL - 50

SP - 1299

EP - 1305

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -